Two compounded tirzepatide programs head-to-head — Mochi's NP-led membership model vs Henry Meds' async intake — on price, oversight, and pharmacy.
| Mochi Health | Henry Meds | |
|---|---|---|
| From / month | $209/mo | $297/mo |
| Medication type | Compounded | Compounded |
| FDA status | Not FDA-approved | Not FDA-approved |
| Clinical oversight | NP-led | Clinician + async intake |
| Pharmacy / fulfillment | 503A | 503A |
| Insurance | Cash-pay (HSA/FSA) | Cash-pay (HSA/FSA) |
Pricing verified as of July 2026 — confirm current figures with each provider. Compounded medications are not FDA-approved.
Both are compounded tirzepatide programs on the 503A pathway. Mochi is NP-led with a membership style; Henry Meds uses asynchronous intake. Neither dispenses an FDA-approved product.
Both fulfill via 503A compounding pharmacies. Compounded tirzepatide is not FDA-approved; ask either provider for a certificate of analysis.
Mochi may suit those wanting a lower price with NP support; Henry Meds may suit those preferring a large async brand. For flat-rate compounded with MD/DO oversight and disclosed 503A/503B pharmacies, see the NexLife review.
Mochi (~$209/mo) is generally lower than Henry Meds (~$297/mo). Both are compounded and not FDA-approved; weigh oversight and pharmacy transparency too. See NexLife pricing
Yes — both dispense compounded tirzepatide via 503A pharmacies, which is not FDA-approved.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.